Analysts Offer Insights on Healthcare Companies: Insmed (NASDAQ: INSM) and Achaogen (NASDAQ: AKAO)


There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Insmed (NASDAQ: INSM) and Achaogen (NASDAQ: AKAO) with bullish sentiments.

Insmed (NASDAQ: INSM)

In a report released today, Andrew Fein from H.C. Wainwright maintained a Buy rating on Insmed (NASDAQ: INSM), with a price target of $35. The company’s shares closed yesterday at $27.42.

According to TipRanks.com, Fein is a 4-star analyst with an average return of 5.4% and a 48.8% success rate. Fein covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Strongbridge Biopharma Plc, and Cyclacel Pharmaceuticals.

Currently, the analyst consensus on Insmed is Strong Buy and the average price target is $42.25, representing a 54.1% upside.

In a report released yesterday, Cowen & Co. also maintained a Buy rating on the stock with a $56 price target.

Find more picks by Best Performing Analysts >>

Achaogen (NASDAQ: AKAO)

H.C. Wainwright analyst Ed Arce maintained a Buy rating on Achaogen (NASDAQ: AKAO) today and set a price target of $19. The company’s shares closed on Tuesday at $14.70.

According to TipRanks.com, Arce is a 5-star analyst with an average return of 20.0% and a 43.1% success rate. Arce covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Collegium Pharmaceutical, and Conatus Pharmaceuticals.

Currently, the analyst consensus on Achaogen is Strong Buy and the average price target is $20.25, representing a 37.8% upside.

In a report issued on April 27, Mizuho Securities also maintained a Buy rating on the stock with a $28 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on AKAO:

Achaogen (AKAO): Will cUTI Asset Impress Today’s AdCom? Cowen Shares Two Cents
Achaogen (AKAO): What Do the FDA’s Briefing Documents Mean for Wednesday’s Big AdCom Meeting? H.C. Wainwright Weighs In
Watch Out for These Pharmaceutical Players Racing Toward FDA Approvals

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts